ArticleInternational journal of molecular sciences2022
Altered Surface Expression of Insulin-Degrading Enzyme on Monocytes and Lymphocytes from COVID-19 Patients Both at Diagnosis and after Hospital Discharge.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 2 institutions in 1 country.
Carlos M González-CasimiroPhysiopathology of Metabolic Diseases Lab, Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Valladolid, 47003 Valladolid (UVa), Spain.ORCID 0000-0003-1640-7457
Elisa Arribas-RodríguezMucosal Immunology Lab, Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Valladolid (UVa), 47003 Valladolid, Spain.
Aida Fiz-LópezMucosal Immunology Lab, Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Valladolid (UVa), 47003 Valladolid, Spain.ORCID 0000-0003-2052-7996
Javier CasasMicroscopy Unit, Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Valladolid (UVa), 47003 Valladolid, Spain.ORCID 0000-0002-6413-8127
Sara GutiérrezInternal Medicine Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.ORCID 0000-0002-7356-470X
Pablo TelleríaInternal Medicine Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.
Cristina NovoaInternal Medicine Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.
Silvia Rojo-RelloMicrobiology and Immunology Unit, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.
Eduardo TamayoDepartment of Surgery, University of Valladolid, 47002 Valladolid, Spain.
Antonio OrduñaMicrobiology and Immunology Unit, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.ORCID 0000-0001-8013-1470
Carlos DueñasInternal Medicine Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.
David BernardoMucosal Immunology Lab, Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Valladolid (UVa), 47003 Valladolid, Spain.
German PerdomoPhysiopathology of Metabolic Diseases Lab, Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Valladolid, 47003 Valladolid (UVa), Spain.ORCID 0000-0002-2301-0012
Universidad de Valladolid · ESHospital Clínico Universitario de Valladolid · ES
Funding
European Commission - NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global)Junta de Castilla y León Proyectos COVID 07.04.467B04.74011.0Junta de Castilla y León and the European Social Fund ORDER EDU/574/2018"La Caixa" Foundation LCF/PR/PR18/51130007MCIN/AEI PID2019-110496RB-C22 by MCIN/AEI/ 10.13039/501100011033Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León (CCVC8485)
6 · The paper itself
Abstract
Although the COVID-19 disease has developed into a worldwide pandemic, its pathophysiology remains to be fully understood. Insulin-degrading enzyme (IDE), a zinc-metalloprotease with a high affinity for insulin, has been found in the interactomes of multiple SARS-CoV-2 proteins. However, the relevance of IDE in the innate and adaptative immune responses elicited by circulating peripheral blood mononuclear cells is unknown. Here, we show that IDE is highly expressed on the surface of circulating monocytes, T-cells (both CD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Altered Surface Expression of Insulin-Degrading Enzyme on Monocytes and Lymphocytes from COVID-19 Patients Both at Diagnosis and after Hospital Discharge. · full record | OpenQuestion